A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis (Micafungin)
Micafungin Anti-Fungal Prophylaxis in Immunocompromised Pediatric Patients: A Pharmacokinetic Study
Sponsor: Astellas Pharma Inc
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Astellas Pharma Inc
- Primary Mitochondrial Myopathy · Phase PHASE2 · May 2024
- Prostate Cancer · Jan 2024
- Anemia · Phase PHASE3 · Jun 2023
- Metastatic Castration Resistant Prostate Cancer · Phase PHASE1/PHASE2 · Nov 2022
- Breast Cancer · Phase PHASE2 · Sep 2022
More terminations from Astellas Pharma Inc
This PHASE1 trial investigates Bone Marrow Transplant and Cancer and is currently terminated or withdrawn. Astellas Pharma Inc leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Feb 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
- Children's Hospital Medical Center, Cincinnati
For direct contact, visit the study record on ClinicalTrials.gov .